Wednesday, February 5, 2025
Home 2022

Yearly Archives: 2022

2022 Watch List

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine...

Editor / Curator -
Mitesco
Research

Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165%...

Editor / Curator -
2021 Watch List

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study...

Editor / Curator -
Marijuana Stock Review

Surna Cultivation Technologies Signs Contract for New Addition to Product Portfolio

Editor / Curator -
Internet News

DCS (DCSX) Announces Strategic Partnership with Streamline Transportation Technologies to Kick-off...

Editor / Curator -
All News

Video: China’s Evergrande. The $300 Billion Unwind has Started. Lehman Bros.,...

Editor / Curator -
All News

Adding Smart for Life (SMFL) $0.85 to the Watch List.

Editor / Curator -
2022 Watch List

Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next...

Editor / Curator -
CEA Industries
All News

Surna Cultivation Technologies Signs $2.1 Million Contract

Editor / Curator -
All News

Adding CEA Industries (CEAD) $2.05 to Watch List.

Editor / Curator -
1...10111213Page 11 of 13

Latest article

Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.

All News Editor / Curator -
119% Gain Post Split

Nine Page Summary Report on GeoVax (GOVX)

2024 Watch List Editor / Curator -
This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

2024 Watch List Editor / Curator -
Award of BARDA Project NextGen contract represents a significant milestone event; Total value...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.